Key result
HCM patients with a biphasic force-frequency relation had significantly lower SERCA2 mRNA levels (0.34) compared to those with a progressive rise (0.72) and controls (0.85).
Why the study?
Is impaired LV contractile reserve in nonobstructive HCM associated with altered gene expression of Ca2+-handling proteins?
Observational (n=21)
Is impaired LV contractile reserve in nonobstructive HCM associated with altered gene expression of Ca2+-handling proteins?
Downregulation of SERCA2 mRNA may contribute to impaired LV contractile reserve in HCM patients with severe hypertrophy, even with preserved baseline systolic function.
BACKGROUND: The relationship between left ventricular (LV) contractile functional reserve and gene expression of Ca(2+)-handling proteins in patients with hypertrophic cardiomyopathy (HCM) remains to be clarified. METHODS AND RESULTS: We calculated the maximum first derivative of LV pressure (LV dP/dt(max)) and the LV pressure half-time (T(1/2)) during pacing in 14 patients with nonobstructive HCM (LV ejection fraction >55%) and 7 control subjects. Endomyocardial tissue was obtained, and mRNA levels of sarcoplasmic reticulum Ca(2+)-ATPase (SERCA2), ryanodine receptor-2, phospholamban, calsequestrin, and Na(+)/Ca(2+) exchanger were quantified by use of a real-time quantitative reverse transcription-polymerase chain reaction method. Group A consisted of 7 HCM patients who showed a progressive rise in the LV dP/dt(max) with increased heart rate. Group B consisted of 7 HCM patients in whom the heart rate-LV dP/dt(max) relation was biphasic at physiological pacing rates. Both the mean maximal wall thickness and the LV hypertrophy score in group B were greater than in group A (20+/-5 versus 15+/-3 mm and 7+/-1 versus 5+/-2 points, respectively). SERCA2 mRNA levels were significantly lower in group B (SERCA2/GAPDH ratio 0.34+/-0.15) compared with group A (0.72+/-0.27) and control subjects (0.85+/-0.47), whereas the mRNA expression of ryanodine receptor-2, phospholamban, calsequestrin, and Na(+)/Ca(2+) exchanger were similar in all groups. CONCLUSIONS: These results suggest that downregulation of SERCA2 mRNA, resulting in altered Ca(2+) handling, may contribute to impaired LV contractile reserve in HCM patients with severe hypertrophy, even in the absence of detectable baseline systolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Somura et al. (2001) conducted an observational in Hypertrophic cardiomyopathy (n=21). Biphasic heart rate-LV dP/dt(max) relation (Group B) vs. Progressive rise in LV dP/dt(max) (Group A) and control subjects was evaluated on SERCA2 mRNA levels (SERCA2/GAPDH ratio). HCM patients with a biphasic force-frequency relation had significantly lower SERCA2 mRNA levels (0.34) compared to those with a progressive rise (0.72) and controls (0.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: